Impact Factor
4.29
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
8.20
969 total citations
h5-index
50
h5 depth signal
Cited share
87.0%
107 of 123
Total citations
969
Citation footprint
Metric signal
8.02
External metric anchor
Self-citation
1.7%
16 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
311
Italy
88
United Kingdom
80
France
47
Netherlands
45
Citing Fields of Research
Hematology
463
Lymphomas
123
Immunology
82
Oncology
42
Cardiology
19
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,891
Articles tracked across the journal lifetime
Indexed publication set
123
107 cited publications
Last 12 months
58
4.8 publications/month
Open access share
60.3%
35 OA publications in the last year
Leading citing country
United States
311 citing publications
Leading citing field
Hematology
463 citing publications
Latest tracked publication
1 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1987-
v1n1, 1987-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hematology
Broad Categories
Hematology
Lymphomas
MeSH Descriptors
Hematology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.blre.2026.101436
Open DOI
The evolving landscape of tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia: A 25-year journey
02
DOI 10.1016/j.blre.2026.101435
Open DOI
Targeting tomorrow: Evaluation of novel agents for infants with KMT2A-rearranged acute lymphoblastic leukaemia
03
DOI 10.1016/j.blre.2026.101434
Open DOI
Beyond the platelet count: A systematic review of artificial intelligence in immune thrombocytopenia
04
DOI 10.1016/j.blre.2026.101433
Open DOI
Neonatal antiphospholipid syndrome–associated thrombosis: Diagnostic pitfalls and therapeutic frontiers
05
DOI 10.1016/j.blre.2026.101432
Open DOI
Sequencing CD19-targeted therapies in patients with relapsed/refractory large B-cell lymphoma: A narrative review
06
DOI 10.1016/j.blre.2026.101431
Open DOI
Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data
07
DOI 10.1016/s0268-960x(26)00063-9
Open DOI
Editorial Board
08
DOI 10.1016/j.blre.2026.101430
Open DOI
Non-transfusion-dependent β-thalassemia: A disease of clinical paradoxes
09
DOI 10.1016/j.blre.2026.101420
Open DOI
Targeting the hepcidin–ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies
10
DOI 10.1016/j.blre.2026.101419
Open DOI
Advances in differentiation syndrome in acute promyelocytic leukemia: From mechanisms to management
Bibliographical & Catalog Notes
Title from cover.
Imprint varies.
Also issued online.
(1988)19890818 Notice published Printed on acid-free paper